Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Chemotherapy, Cancer, Regional Perfusion × Clear all
NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡